FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.
Ying-Hao Shen(Fudan University), Hui‐Chuan Sun(Fudan University), Jian Zhou(Ministry of Education of the People's Republic of China), Yanan Chen(South China Agricultural University), Xiaoli Zhu(Soochow University), Fan Jia(Sir Run Run Shaw Hospital), Tao Huang(Union Hospital), Wenlong Zhai(Zhengzhou University), Zhihu Li(Harbin Medical University), Zhiwei Li(Changsha University of Science and Technology)
Cited by 1
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Inhibition of JNK activation through NF-κB target genes
|Nature|2001|719
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644